20 research outputs found
PP078âComparison of a new elisa-based with the flow cytometric assay for vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation to assess P2Y12-inhibition after ticagrelor intake
How was Lake Derborence (VS, Switzerland) formed? Popularisation of Geosciences by means of a geotourist map
Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients
OBJECTIVE: The present study investigated whether the glycoprotein (GP)IIb/IIIa receptor blocker abciximab might be a successful bridging strategy to achieve adequate levels of platelet inhibition rapidly in cases where prasugrel is used in morphineâpretreated STâelevation myocardial infarction (STEMI) patients. METHODS: In a prospective observational cohort study, 32 patients presenting with STEMI were given prasugrel at a loading dose of 60Â mg. Patients were stratified into four groups, according to morphine and/or abciximab use. Adenosine diphosphate (ADP)âinduced platelet aggregation was measured at four time points: at baseline, and at 2Â h, 1Â day and 2Â days after prasugrel loading. RESULTS: Morphine use was associated with a threeâfold higher level of ADPâinduced platelet aggregation 2Â h after prasugrel loading compared with no morphine/no abciximab (P = 0.019). However, when abciximab was infused in the catheterization laboratory, the effect of morphine on ADPâinduced platelet aggregation disappeared (P = 0.884). This interaction was also seen in the presence of high onâtreatment platelet reactivity (HTPR) at 2 h; while HTPR was seen in 88% of morphine users/no abciximab users, it was found in only 17â20% in the three other groups (P = 0.003). The effect of morphine disappeared by day 1 â 2. CONCLUSION: The infusion of the GPIIb/IIIa receptor blocker abciximab allows immediate and efficient platelet inhibition in STEMI patients concomitantly receiving the oral ADP receptor blocker prasugrel and morphine
Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine
Separation of Aliphatic and Aromatic Carboxylic Acids by Conventional and Ultra High-Performance Ion-Exclusion Chromatography
PUMA, antiProton unstable matter annihilation
International audiencePUMA, antiProton Unstable Matter Annihilation, is a nuclear-physics experiment at CERN aiming at probing the surface properties of stable and rare isotopes by use of low-energy antiprotons. Low-energy antiprotons offer a very unique sensitivity to the neutron and proton densities at the annihilation site, i.e. in the tail of the nuclear density. Today, no facility provides a collider of low-energy radioactive ions and low-energy antiprotons: while not being a collider experiment, PUMA aims at transporting one billion antiprotons from ELENA, the Extra-Low-ENergy Antiproton ring, to ISOLDE, the rare-isotope beam facility of CERN. PUMA will enable the capture of low-energy antiprotons by short-lived nuclei and the measurement of the emitted radiations. In this way, PUMA will give access to the so-far largely unexplored isospin composition of the nuclear-radial-density tail of radioactive nuclei. The motivations, concept and current status of the PUMA experiment are presented